A Trial Evaluating the Pharmacodynamic Response of NN1250 at Steady State in Subjects With Type 2 Diabetes

NCT01154881 Phase 1 COMPLETED

This trial was conducted in Europe. The aim of this clinical trial was to evaluate the blood glucose-lowering effect of NN1250 (insulin degludec/insulin 454) in subjects with type 2 diabetes.

Details

Lead sponsor	Novo Nordisk A/S
Phase	Phase 1
Status	COMPLETED
Enrolment	49
Start date	2010-06
Completion	2010-11

Conditions

• Diabetes
• Diabetes Mellitus, Type 2

Interventions

• insulin degludec

Primary outcomes

• Area under the glucose infusion rate curve from 0-24 hours at steady state — 0-24 hours (derived on treatment day 6)

Countries

Germany